Kollywood actor Vivekh passed away at 4.35 am this morning (Photo | EPS) 
Chennai

Vivekh’s death not related to Covid vaccine: Chennai Corp commissioner

Corporation officials said that around 9.8 lakh people in Chennai had received the vaccine first dose.

Express News Service

CHENNAI: Pointing out that the medical details over actor Vivekh’s death have revealed that it had nothing to do with the Covid vaccine that he received on Thursday, Chennai Corporation Commissioner G Prakash said that the civic body will continue to create awareness on the necessity to take the jab.

Corporation officials said that around 9.8 lakh people in Chennai had received the vaccine first dose. “No major side effect has been reported and around 1.33 lakh people have taken second dose. A few people reported minor side effects,” said Corporation Deputy Commissioner, Alby John.

The officials were inspecting one of the 12 triage centres relaunched in the city. Covid patients will be brought to these centres for basic tests. Vaccines would not be provided at these triage centres. “As many as 200 fever camps are being held to contain the spread,” G Prakash said.

Triage centres in Chennai

  • Tiruvottiyur Government Hospital  
  • Madhavaram Government Hospital 
  • Communicable Diseases Hospital in Tondiarpet  
  • Bharathi Women’s College in Royapuram  
  • ESI Ayanavaram  Community Hall at Mogappair  
  • Ayanavaram Government School  Victoria Hostel at Teynampet  
  • Corporation Higher Secondary School in Nesapakkam  
  • Hussaini School in Valasaravakkam zone  
  • National Skill Training Institute in Guindy  
  • Teacher Training Institute in Karapakkam

Trump says US will be out of Iran 'pretty quickly' as Tehran rubbishes claims of seeking ceasefire

Amid Opposition protests and Kerala poll concerns, Centre drops debate on new FCRA bill

Punjab begins first-ever drug and socio-economic census; 28,000 employees to survey 65 lakh families

Minister Sekar Babu hopes Harbour will remain his fiefdom

Tech hiring slips 8% in April, reversing early 2026 gains

SCROLL FOR NEXT